Research provides framework for developing Ebola virus therapeutic under animal rule

The US Army Medical Research Institute of Infectious Diseases (USAMRIID) announced that, for the first time, the US Food and Drug Administration (FDA) has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus infections.

MMV and DNDi make 400 compounds available to stimulate research into new drugs for pandemic diseases

Medicines for Malaria Venture (MMV) and the Drugs for Neglected Diseases initiative (DNDi) have launched the Pandemic Response Box to provide researchers with free access to 400 diverse compounds to accelerate the discovery of new treatments for life-threatening pandemic diseases.

Setting our sights on infectious diseases

The aim of the conference is to harness cross-disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate attrition rates for infectious diseases affecting low and middle income countries. Conference attendees will take home new ideas and technologies which have been demonstrated to work; applying them to diseases where challenges to drug discovery are hampering progress.

Building a public library of bacteria to facilitate drug discovery research

Coupled with a novel web-based bioinformatics pipeline, the researchers hope the library, which will not only provide information to help classify bacteria but also will help identify the antibiotics an individual species might produce, will remove years of work from the drug discovery process.